Back to Search Start Over

A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias.

Authors :
Gruszka AM
Lavorgna S
Consalvo MI
Ottone T
Martinelli C
Cinquanta M
Ossolengo G
Pruneri G
Buccisano F
Divona M
Cedrone M
Ammatuna E
Venditti A
de Marco A
Lo-Coco F
Pelicci PG
Source :
Blood [Blood] 2010 Sep 23; Vol. 116 (12), pp. 2096-102. Date of Electronic Publication: 2010 Jun 10.
Publication Year :
2010

Abstract

Mutations in the nucleophosmin 1 (NPM1) gene are the most frequent genetic aberrations of acute myeloid leukemia (AML) and define a clinically distinct subset of AML. A monoclonal antibody (T26) was raised against a 19-amino acid polypeptide containing the unique C-terminus of the type A NPM1 mutant protein. T26 recognized 10 of the 21 known NPM1 mutants, including the A, B, and D types, which cover approximately 95% of all cases, and did not cross-react with wild-type NPM1 or unrelated cellular proteins. It performed efficiently with different detection technologies, including immunofluorescence, immunohistochemistry, and flow cytometry. Within a series of consecutive de novo AML patients, 44 of 110 (40%) and 15 of 39 (38%) cases scored positive using the T26 antibody in immunofluorescence and flow cytometry assays, respectively. T26-positive cases were found to be all carrying mutations of NPM1 exclusively, as determined by molecular analysis. T26 is the first antibody that specifically recognizes a leukemia-associated mutant protein. Immunofluorescence or flow cytometry using T26 may thus become a new tool for a rapid, simple, and cost-effective molecular diagnosis of AMLs.

Details

Language :
English
ISSN :
1528-0020
Volume :
116
Issue :
12
Database :
MEDLINE
Journal :
Blood
Publication Type :
Academic Journal
Accession number :
20538791
Full Text :
https://doi.org/10.1182/blood-2010-01-266908